Loading company
Latigo Biotherapeutics, Inc.
LTGO · Nasdaq · ·
$18.10+4.2%Sep 29 close
- 1M
- -25.3%
LTGO · Nasdaq · ·
$18.10+4.2%Sep 29 close
From the company’s own 8-K filing.
Latigo Biotherapeutics, Inc. has no earnings call transcript available.
“This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Latigo’s drug candidates are designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The Company’s lead product candidate, onzotrigine (previously referred to as LTG-001) is an oral Na v 1.8 ion channel inhibitor intended to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is an oral Na v 1.8 inhibitor being developed for chronic musculoskeletal pain. Additionally, Latigo is advancing research of additional Na v 1.8 inhibitors that can address alternative formulation and delivery approaches as well as other ion channel targets for the treatment of pain. Learn more at latigobio.com or follow us on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Latigo Biotherapeutics, Inc.’s Item 2.02 8-K filed September 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.